Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Shares of Japan's Sumitomo Pharma fell over 12% on the back of profit-taking after a specialist panel endorsed its iPS cell-based therapy for Parkinson's disease.
By CNBC · CNBC
Shares of Japan's Sumitomo Pharma fell over 12% on the back of profit-taking after a specialist panel endorsed its iPS cell-based therapy for Parkinson's disease.